PYC Therapeutics Ltd banner

PYC Therapeutics Ltd
F:PH7

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
F:PH7
Watchlist
Price: 0.065 EUR Market Closed
Market Cap: €290.7m

Intrinsic Value

PH7 price has not been updated for more than 1 year. This may indicate that the stock has been delisted.

The intrinsic value for PYC Therapeutics Ltd (PH7) under the Base Case is 0.103 EUR. Compared with the current market price of 0.065 EUR, the stock appears Undervalued by 37% .

Based on two methods:

DCF suggests undervaluation, while multiples suggest overvaluation.

PH7 Intrinsic Value
0.103 EUR
Undervaluation 37%
Intrinsic Value
Price €0.065
Base Case Scenario
Monitor PH7
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €0.08
Get notified when the price drops into your buy zone
Intrinsic Value €0.1
Margin of Safety 20% €0.08
Current Price €0.07
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about PH7?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PH7 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for PYC Therapeutics Ltd.

Explain Valuation
Alternatives to PH7

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one PH7 stock?

The intrinsic value for PYC Therapeutics Ltd (PH7) under the Base Case is 0.103 EUR.

Is PH7 stock undervalued or overvalued?

Compared with the current market price of 0.065 EUR, the stock appears Undervalued by 37% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett